

#34



Form PTO-1449
U.S. DEPARTMENT OF COMMERCE (Rev. 7-80)
PATENT AND TRADEMARK OFFICE

LIST OF PRIOR ART CITED BY APPLICANT
(Use several sheets if necessary)

ATTORNEY DOCKET NO.: 14014.0312

SERIAL NO. 09/196,867

APPLICANT: Kelsall et al

FILING DATE: November 20, 1998

GROUP: 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Bo	C1	Gordon <i>et al.</i> , "Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis," <i>J Neuroimmunology</i> 62: 153-160, 1995
	C2	Rosen, Hugh "Role of CR3 in Induced Myelomonocytic Recruitment: Insights From In Vivo Monoclonal Antibody Studies in the Mouse," <i>J Leuk. Biol.</i> 48: 465-469, 1990
	C3	Rosen <i>et al.</i> , "Antibody To the Murine Type 3 Complement Receptor Inhibits T Lymphocyte-Dependent Recruitment of Myelomonocytic Cells In Vivo," <i>J Exp. Med.</i> 169: 535-548, 1989
	C4	Rosen and Gordon "Monoclonal Antibody To The Murine Type 3 Complement Receptor Inhibits Adhesion of Myelomonocytic Cells in Vitro and Inflammatory Cell Recruitment In Vivo," <i>J. Exp. Med.</i> 166: 1685-1701, 1987

EXAMINER: *Am R. Cherry*

DATE CONSIDERED: *9-26-02*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
JUL 10 2002
TECH CENTER 1600/2900